Spots Global Cancer Trial Database for taxane
Every month we try and update this database with for taxane cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pharmacokinetic, Safety and Tolerability Study of SPARC1028 | NCT01305512 | Solid Tumor in ... | SPARC1028 | 18 Years - | Sun Pharma Advanced Research Company Limited | |
| Randomized Study of Elective Regional Lymph Node Irradiation in N1 Breast Cancer | NCT03269981 | Breast Neoplasm | Whole breast ir... Whole breast an... | 20 Years - 70 Years | Samsung Medical Center | |
| Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination | NCT01304303 | Solid Tumor in ... | SPARC1023 I SPARC1023 II | 18 Years - | Sun Pharma Advanced Research Company Limited | |
| Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma | NCT00044564 | Carcinoma, Rena... | Bay 59-8862 | 18 Years - | Bayer | |
| Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia | NCT02024568 | Taxane Drug-related Si... Pain Breast Cancer | Pregabalin Placebo | 18 Years - | Assaf-Harofeh Medical Center | |
| A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer | NCT00553813 | Pancreatic Canc... | TPI 287 | 18 Years - | Cortice Biosciences, Inc. | |
| A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy | NCT00267007 | Peripheral Neur... | PROCRIT 40,000 ... Placebo | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | NCT02134067 | Advanced Solid ... | TAS-119 Paclitaxel | 18 Years - | Taiho Oncology, Inc. | |
| Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer | NCT05843292 | Triple-negative... | Taxane and Carb... Short-term Sint... Surgery | 18 Years - 70 Years | Shanghai Jiao Tong University School of Medicine | |
| A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer | NCT00970580 | Non-Small Cell ... | BIIB022 With Pa... | 18 Years - | Biogen | |
| Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen | NCT00191269 | Metastatic Brea... | gemcitabine gemcitabine | 20 Years - 74 Years | Eli Lilly and Company | |
| Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC | NCT03952325 | Breast Cancer | Tesetaxel Tesetaxel Tesetaxel Nivolumab Pembrolizumab Atezolizumab Tesetaxel | 18 Years - | Odonate Therapeutics, Inc. | |
| Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | NCT04784715 | Breast Cancer; ... | Trastuzumab der... Placebo Taxane Pertuzumab Trastuzumab | 18 Years - 130 Years | AstraZeneca | |
| Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer | NCT01348009 | Gastric Carcino... | Tesetaxel-capec... | 20 Years - | Genta Incorporated | |
| Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma | NCT02402842 | Anal Canal Carc... | Docetaxel, Cisp... | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma | NCT00044551 | Lymphoma, Non-H... | Taxane (Cytotox... | 18 Years - | Bayer | |
| Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | NCT02134067 | Advanced Solid ... | TAS-119 Paclitaxel | 18 Years - | Taiho Oncology, Inc. | |
| Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial) | NCT02441933 | Breast Cancer | taxane plus car... Taxane | 19 Years - | Yonsei University | |
| A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer | NCT02685306 | Breast Cancer Triple Negative... Triple-Negative... Triple-Negative... Triple Negative... ER-Negative PR-... ER-Negative PR-... | Bavituximab Taxane | 18 Years - | Peregrine Pharmaceuticals | |
| Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial) | NCT02441933 | Breast Cancer | taxane plus car... Taxane | 19 Years - | Yonsei University | |
| Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma | NCT00044564 | Carcinoma, Rena... | Bay 59-8862 | 18 Years - | Bayer | |
| Phase I/IIa Study of Pharmacokinetics and Safety of Epidiferphane™ and Taxanes in Breast Cancer Patients | NCT03611985 | Breast Cancer | Epidiferphane Taxane Chemothe... | 18 Years - 99 Years | University of Florida | |
| Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | NCT02134067 | Advanced Solid ... | TAS-119 Paclitaxel | 18 Years - | Taiho Oncology, Inc. | |
| A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer | NCT00479635 | Prostate Cancer | TPI 287 TPI 287 | 18 Years - | Cortice Biosciences, Inc. | |
| Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse | NCT00849667 | Ovarian Cancer | Farletuzumab Carboplatin Taxane Farletuzumab-ma... | 18 Years - | Morphotek | |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC | NCT05670106 | Metastatic Cast... | [177Lu]Lu-PSMA-... Best supportive... 68Ga-PSMA-11 | 18 Years - | Novartis | |
| Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer | NCT02651610 | Metastatic Brea... | Bavituximab Taxane | 18 Years - | Peregrine Pharmaceuticals | |
| Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy | NCT01682499 | Paclitaxel-indu... | calcium glucona... | 21 Years - | Beth Israel Medical Center | |
| A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer | NCT00553813 | Pancreatic Canc... | TPI 287 | 18 Years - | Cortice Biosciences, Inc. | |
| RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | NCT02489903 | Small Cell Carc... Carcinoma, Non-... Neuroendocrine ... Ovarian Epithel... | RRx-001 Cisplatin Etoposide Carboplatin Irinotecan Vinorelbine Doxil Gemcitabine Taxane Paclitaxel Nab-Paclitaxel Pemetrexed | 18 Years - | EpicentRx, Inc. | |
| Randomized Study of Elective Regional Lymph Node Irradiation in N1 Breast Cancer | NCT03269981 | Breast Neoplasm | Whole breast ir... Whole breast an... | 20 Years - 70 Years | Samsung Medical Center | |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC | NCT05670106 | Metastatic Cast... | [177Lu]Lu-PSMA-... Best supportive... 68Ga-PSMA-11 | 18 Years - | Novartis | |
| EPO906 Therapy in Patients With Advanced Breast Cancer | NCT00035126 | Breast Neoplasm... | epothilone b | 18 Years - 85 Years | Novartis | |
| Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer | NCT05843292 | Triple-negative... | Taxane and Carb... Short-term Sint... Surgery | 18 Years - 70 Years | Shanghai Jiao Tong University School of Medicine | |
| A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer | NCT02685306 | Breast Cancer Triple Negative... Triple-Negative... Triple-Negative... Triple Negative... ER-Negative PR-... ER-Negative PR-... | Bavituximab Taxane | 18 Years - | Peregrine Pharmaceuticals | |
| Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer | NCT02125019 | Breast Cancer | 18 Years - | Ohio State University Comprehensive Cancer Center | ||
| Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer | NCT00046527 | Breast Neoplasm... Metastases, Neo... | ABI-007 | 16 Years - | Celgene Corporation | |
| A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer | NCT00479635 | Prostate Cancer | TPI 287 TPI 287 | 18 Years - | Cortice Biosciences, Inc. | |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer | NCT06102824 | HER2-negative B... Advanced Breast... | Organoid-guided... Taxane Capecitabine Gemcitabine Vinorelbine Eribulin Anthracycline Carboplatin Utidelone Trastuzumab der... Sacituzumab gov... | 18 Years - 80 Years | Guangdong Provincial People's Hospital | |
| Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer | NCT00387907 | Advanced Breast... Breast Cancer Metastatic Brea... | larotaxel (XRP9... trastuzumab | 18 Years - | Sanofi | |
| Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors | NCT04931823 | Solid Tumor | CPO-100 | 18 Years - | Conjupro Biotherapeutics, Inc. | |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer | NCT06102824 | HER2-negative B... Advanced Breast... | Organoid-guided... Taxane Capecitabine Gemcitabine Vinorelbine Eribulin Anthracycline Carboplatin Utidelone Trastuzumab der... Sacituzumab gov... | 18 Years - 80 Years | Guangdong Provincial People's Hospital | |
| Cryotherapy vs. Cryocompression for Preventing Chemotherapy-induced-peripheral-neuropathy in Women Undergoing Chemotherapy | NCT04632797 | Chemotherapy-in... Chemotherapeuti... Chemotherapeuti... | Hilotherm Chemo... | 18 Years - 99 Years | Medical University Innsbruck | |
| Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients | NCT00044538 | Carcinoma, Non-... | BAY59-8862 (Cyt... | 18 Years - | Bayer | |
| Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer | NCT02766582 | Ovarian Cancer | Pembrolizumab Carboplatin Paclitaxel | 18 Years - | Medical College of Wisconsin | |
| Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer | NCT00046527 | Breast Neoplasm... Metastases, Neo... | ABI-007 | 16 Years - | Celgene Corporation | |
| A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer | NCT00970580 | Non-Small Cell ... | BIIB022 With Pa... | 18 Years - | Biogen | |
| Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients | NCT00044525 | Breast Neoplasm... Breast Cancer, ... | BAY59-8862 (Cyt... | 18 Years - | Bayer | |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer | NCT06102824 | HER2-negative B... Advanced Breast... | Organoid-guided... Taxane Capecitabine Gemcitabine Vinorelbine Eribulin Anthracycline Carboplatin Utidelone Trastuzumab der... Sacituzumab gov... | 18 Years - 80 Years | Guangdong Provincial People's Hospital | |
| Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(SYSUGO-005/CSEM009) | NCT02624531 | Cervical Cancer | Taxane radical trachel... | 18 Years - 40 Years | Sun Yat-sen University | |
| Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients | NCT00044538 | Carcinoma, Non-... | BAY59-8862 (Cyt... | 18 Years - | Bayer | |
| Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC | NCT03952325 | Breast Cancer | Tesetaxel Tesetaxel Tesetaxel Nivolumab Pembrolizumab Atezolizumab Tesetaxel | 18 Years - | Odonate Therapeutics, Inc. | |
| Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer | NCT01692483 | Prostate Neopla... | Abiraterone ace... Prednisone | 18 Years - | Janssen Pharmaceutica | |
| Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients | NCT00044525 | Breast Neoplasm... Breast Cancer, ... | BAY59-8862 (Cyt... | 18 Years - | Bayer | |
| Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer | NCT01049425 | Primary Breast ... Her2 Non-overex... | Epirubicin Cyclophosphamid... Docetaxel Cyclophosphamid... Docetaxel | 18 Years - 75 Years | West German Study Group | |
| Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer | NCT01049425 | Primary Breast ... Her2 Non-overex... | Epirubicin Cyclophosphamid... Docetaxel Cyclophosphamid... Docetaxel | 18 Years - 75 Years | West German Study Group | |
| Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer | NCT01049425 | Primary Breast ... Her2 Non-overex... | Epirubicin Cyclophosphamid... Docetaxel Cyclophosphamid... Docetaxel | 18 Years - 75 Years | West German Study Group | |
| EPO906 Therapy in Patients With Advanced Breast Cancer | NCT00035126 | Breast Neoplasm... | epothilone b | 18 Years - 85 Years | Novartis | |
| Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients | NCT04920747 | HER2-positive G... Metastatic Canc... Docetaxel Trastuzumab | Taxane | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients | NCT03872141 | Breast Cancer Chemotherapy In... Paclitaxel Indu... | Quantitative me... | 18 Years - 70 Years | Yale University | |
| Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen | NCT00191269 | Metastatic Brea... | gemcitabine gemcitabine | 20 Years - 74 Years | Eli Lilly and Company | |
| Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination | NCT01304303 | Solid Tumor in ... | SPARC1023 I SPARC1023 II | 18 Years - | Sun Pharma Advanced Research Company Limited | |
| Phase I/IIa Study of Pharmacokinetics and Safety of Epidiferphane™ and Taxanes in Breast Cancer Patients | NCT03611985 | Breast Cancer | Epidiferphane Taxane Chemothe... | 18 Years - 99 Years | University of Florida | |
| Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer | NCT01438307 | Non-small Cell ... Stage IV NSCLC Metastatic NSCL... | Cabazitaxel-XRP... Cabazitaxel-XRP... | 19 Years - | University of Alabama at Birmingham |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
